The present invention relates a specific tetrahydroisoquinoline compound which is useful as a chemokine receptor type 3 (CCR3) antagonist, and a pharmaceutical composition comprising the same as an active ingredient. The tetrahydroisoquinoline compound of the present invention is useful for the treatment or prevention of a disease in which CCR3 participates.
Oxidative cyclization of 3-isoquinolyl ketone hydrazones afforded the novel tricyclic heteroaromatic [1,2,3]triazolo[1,5-b]isoquinolinium salts. The reactivity of the ring system towards nucleophiles proved to be regioselective. Secondary amines induced ring opening of the pyridine moiety, forming a triazolyl substituted benzaldehyde derivative; sodium borohydride afforded partially reduced derivatives of the parent compound.
US8273766B2
申请人:——
公开号:US8273766B2
公开(公告)日:2012-09-25
Enantioselective, Catalytic Trichloromethylation through Visible-Light-Activated Photoredox Catalysis with a Chiral Iridium Complex
An enantioselective, catalytic trichloromethylation of 2-acyl imidazoles and 2-acylpyridines is reported. Several products are formed with enantiomeric excess of ≥99%. In this system, a chiral iridium complex serves a dual function, as a catalytically active chiral Lewis acid and simultaneously as a precursor for an in situ assembled visible-light-triggered photoredox catalyst.